Trial Profile
Antiestrogen vs aromatase inhibitor after chemotherapy for adjuvant setting: efficacy of endocrine therapy after chemotherapy in postoperative adjuvant therapy for breast cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Toremifene (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 06 Sep 2013 New source identified and integrated (University Hospital Medical Information Network - Japan; UMIN000000610).
- 29 Mar 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
- 29 Mar 2012 Planned end date changed from 1 May 2010 to 1 May 2020 as reported by ClinicalTrials.gov.